menu
    • menu
    [{"orgOrder":0,"company":"Octavius Pharma Pvt. Ltd","sponsor":"Senta Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Menthol","moa":"||Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Octavius Pharma Pvt. Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Octavius Pharma Pvt. Ltd \/ Senta Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Octavius Pharma Pvt. Ltd \/ Senta Pharma"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Immunology","graph2":"Undisclosed","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Innocan Pharma \/ Research Capital Corporation"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Research Capital Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Innocan Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection, Sustained Release","sponsorNew":"Innocan Pharma \/ Research Capital Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Innocan Pharma \/ Research Capital Corporation"},{"orgOrder":0,"company":"GSK","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Camphor","moa":"||TRPV1","graph1":"Neurology","graph2":"Approved FDF","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"GSK \/ Angelini Pharma","highestDevelopmentStatusID":"15","companyTruncated":"GSK \/ Angelini Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for (-)-Camphor

    Menu

    (-)-Camphor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Octavius Pharma Pvt. Ltd

                            India
                            MAGHREB PHARMA
                            Stand #B09
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothOctavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.

                            Lead Product(s) : Menthol,Camphor

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Senta Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Crampsal Cream (Pain Relief Cream) – Launched in Sudan

                            Details : Crampsal Cream (pain relieving oils) is a non-greasy pain relief cream with mixture of pain-relieving oils, menthol & camphor. It penetrates deep into the skin and provides long lasting relief.

                            Product Name : Crampsal

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 29, 2021

                            Lead Product(s) : Menthol,Camphor

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Senta Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Octavius Pharma

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Innocan Pharma

                            Israel arrow
                            Interphex
                            Not Confirmed

                            Innocan Pharma

                            Israel arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Camphor

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Research Capital Corporation

                            Deal Size : Undisclosed

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Innocan Pharma Announces Closing of First Tranche Private Placement and Provides Corporate Update

                            Details : The Company intends to use the net proceeds from the Offering to fund the Company's pre-investigational new drug meeting with the United States FDA regarding the human application and expansion of the Company's derma-cosmetic product distribution.

                            Product Name : LPT-CBD

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            December 10, 2023

                            Lead Product(s) : Cannabidiol,Camphor

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Research Capital Corporation

                            Deal Size : Undisclosed

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Innocan Pharma

                            Israel arrow
                            Interphex
                            Not Confirmed

                            Innocan Pharma

                            Israel arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Camphor

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Research Capital Corporation

                            Deal Size : $1.6 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Innocan Pharma Announces Closing of Second and Final Tranche of Financing

                            Details : The Company intends to use the net proceeds to fund the Company's pre-investigational new drug meeting regarding the human application of the Company's products, including Cannabidiol.

                            Product Name : LPT-CBD

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            October 20, 2023

                            Lead Product(s) : Cannabidiol,Camphor

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Research Capital Corporation

                            Deal Size : $1.6 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            GSK

                            United Kingdom arrow
                            Interphex
                            Not Confirmed

                            GSK

                            United Kingdom arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Camphor,Capsicum Oleoresin

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Angelini Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Angelini Pharma Acquires ThermaCare® From GSK

                            Details : The acquired asset supports Angelini Pharma reinforcing both its Consumer Healthcare business and consolidating its International presence.

                            Product Name : ThermaCare

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 03, 2020

                            Lead Product(s) : Camphor,Capsicum Oleoresin

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Angelini Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth